Skip to main content
VivoSim Labs, INC. logo

VivoSim Labs, INC. — Investor Relations & Filings

Ticker · VIVS ISIN · US68620A2033 US Professional, scientific and technical activities
Open in API
Filings indexed 790 across all filing types
Latest filing 2018-02-14 Major Shareholding Noti…
Country US United States of America
Listing US VIVS

About VivoSim Labs, INC.

https://organovo.com/

VivoSim Labs, Inc. is a biotechnology services company that develops and utilizes bioprinted, three-dimensional (3D) human tissues designed to emulate human biology and disease. The company provides testing services for drugs and drug candidates, primarily for the pharmaceutical and biotechnology sectors. VivoSim Labs specializes in offering liver and intestinal toxicology insights through its proprietary New Approach Methodologies (NAMs), including its NAMkind™ 3D models. These non-animal testing platforms are used to generate human-relevant safety and toxicology data early in the drug discovery and development process, aiming to provide insights before animal studies or clinical trials.

Recent filings

Filing Released Lang Actions
SC 13G
Major Shareholding Notification
2018-02-14 English
FORM S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is a registration statement used for securities offerings under the Securities Act of 1933. It includes details about the securities to be offered, the registration fee, and the terms of the offering. This type of filing is related to capital raising activities and financing. It is not an annual report, earnings release, or any other financial report but a regulatory filing specifically for securities registration and capital raising. According to the filing definitions, updates on company fundraising or financing activities fall under Capital/Financing Update (CAP). Therefore, this document should be classified as CAP.
2018-02-08 English
10-Q
Interim / Quarterly Report 9M 2018
2018-02-08 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 8, 2018, reporting the issuance of a press release announcing financial results for the third quarter ended December 31, 2017. The document explicitly states it is furnishing a press release with financial results, which is typical of an Earnings Release. The document length is 3419 characters, which is short and mainly serves as a cover for the press release. However, the press release itself is attached as Exhibit 99.1 and is the actual earnings announcement. Since the 8-K includes the earnings press release announcing quarterly financial results, this fits the definition of an Earnings Release (ER).
2018-02-08 English
Major Shareholding Notification 2018
Major Shareholding Notification
2018-01-29 English
PRIMARY DOCUMENT
Director's Dealing
2017-12-04 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.